At a glance
- Originator Corixa Corporation
- Class
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Reperfusion injury
Most Recent Events
- 11 Nov 2003 No development reported - Phase-II for Ischaemic heart disorders in USA (Parenteral)
- 11 Nov 2003 No development reported - Phase-II for Reperfusion injury in USA (Parenteral)
- 14 Nov 2001 Phase-II clinical trials for Ischaemic heart disorders in USA (Parenteral)